Zobrazeno 1 - 10
of 267
pro vyhledávání: '"Guillaume, Charpentier"'
Autor:
Sarah Meulebrouck, Judith Merrheim, Gurvan Queniat, Cyril Bourouh, Mehdi Derhourhi, Mathilde Boissel, Xiaoyan Yi, Alaa Badreddine, Raphaël Boutry, Audrey Leloire, Bénédicte Toussaint, Souhila Amanzougarene, Emmanuel Vaillant, Emmanuelle Durand, Hélène Loiselle, Marlène Huyvaert, Aurélie Dechaume, Victoria Scherrer, Piero Marchetti, Beverley Balkau, Guillaume Charpentier, Sylvia Franc, Michel Marre, Ronan Roussel, Raphaël Scharfmann, Miriam Cnop, Mickaël Canouil, Morgane Baron, Philippe Froguel, Amélie Bonnefond
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Functional genetics has identified drug targets for metabolic disorders. Opioid use impacts metabolic homeostasis, although mechanisms remain elusive. Here, we explore the OPRD1 gene (encoding delta opioid receptor, DOP) to understand its im
Externí odkaz:
https://doaj.org/article/78b374b3ff9b43728d9fb6ee8aab174e
Autor:
Arnaud Dance, Justine Fernandes, Bénédicte Toussaint, Emmanuel Vaillant, Raphaël Boutry, Morgane Baron, Hélène Loiselle, Beverley Balkau, Guillaume Charpentier, Sylvia Franc, Mark Ibberson, Michel Marre, Marie Gernay, Marjorie Fadeur, Nicolas Paquot, Martine Vaxillaire, Mathilde Boissel, Souhila Amanzougarene, Mehdi Derhourhi, Amna Khamis, Philippe Froguel, Amélie Bonnefond
Publikováno v:
Molecular Metabolism, Vol 79, Iss , Pp 101867- (2024)
Objective: Human functional genomics has proven powerful in discovering drug targets for common metabolic disorders. Through this approach, we investigated the involvement of the purinergic receptor P2RY1 in type 2 diabetes (T2D). Methods: P2RY1 was
Externí odkaz:
https://doaj.org/article/f86705b80e164285981d1a94e006f43d
Autor:
Dured Dardari, Sylvia Franc, Guillaume Charpentier, Laurent Orlando, Elise Bobony, Marie Bouly, Ilham Xhaard, Zohra Amrous, Khadijatou Ly Sall, Bruno Detournay, Alfred Penfornis
Publikováno v:
The Lancet Regional Health. Europe, Vol 32, Iss , Pp 100686- (2023)
Summary: Background: Two randomised controlled trials (RCTs) have previously shown that telemedical monitoring of diabetic foot ulcer (DFU) reduces the number of visits to the outpatient clinic, without losing treatment efficacy or increasing costs.
Externí odkaz:
https://doaj.org/article/539274750174469fba2612d0ecbf9d8a
Autor:
Dulanjalee Kariyawasam, MD, Carole Morin, MD, Kristina Casteels, ProfMD, Claire Le Tallec, MD, Annie Sfez, MD, Cécile Godot, MD, Erik Huneker, MSc, Nathalie Garrec, MD, Pierre-Yves Benhamou, ProfMD, Michel Polak, ProfMD, Guillaume Charpentier, MD, Sylvia Franc, MD, Jacques Beltrand, ProfMD
Publikováno v:
The Lancet: Digital Health, Vol 4, Iss 3, Pp e158-e168 (2022)
Summary: Background: Time in range (TIR) goals are rarely met in children with type 1 diabetes, except at the cost of increased hypoglycaemia episodes. Our objective was to evaluate the safety and efficiency of the Diabeloop DBL4K (Diabeloop, Grenobl
Externí odkaz:
https://doaj.org/article/61c960e03c0742cbbfa664fac8d4afc7
Autor:
Dured Dardari, Louis Potier, Ariane Sultan, Maude Francois, Jocelyne M’Bemba, Benjamin Bouillet, Lucy Chaillous, Laurence Kessler, Aurelie Carlier, Abdulkader Jalek, Ayoub Sbaa, Laurent Orlando, Elise Bobony, Bruno Detournay, Hilmar Kjartansson, Ragna Bjorg Arsaelsdottir, Baldur Tumi Baldursson, Guillaume Charpentier
Publikováno v:
Medicina, Vol 58, Iss 12, p 1775 (2022)
Background: Cell and/or tissue-based wound care products have slowly advanced in the treatment of non-healing ulcers, however, few studies have evaluated the effectiveness of these devices in the management of severe diabetic foot ulcers. Method: Thi
Externí odkaz:
https://doaj.org/article/052b407877b848a895d58a646bc4cd1d
Autor:
Lise Folon, Morgane Baron, Bénédicte Toussaint, Emmanuel Vaillant, Mathilde Boissel, Victoria Scherrer, Hélène Loiselle, Audrey Leloire, Alaa Badreddine, Beverley Balkau, Guillaume Charpentier, Sylvia Franc, Michel Marre, Soulaimane Aboulouard, Michel Salzet, Mickaël Canouil, Mehdi Derhourhi, Philippe Froguel, Amélie Bonnefond
Publikováno v:
The Lancet Diabetes & Endocrinology. 11:182-190
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ff1e642d1cfc1f42df82ce93969d4eb
https://doi.org/10.1016/s2213-8587(22)00392-8
https://doi.org/10.1016/s2213-8587(22)00392-8
Autor:
Pierre‐Yves Benhamou, Alice Adenis, Hocine Lebbad, Yousra Tourki, Maria‐Belen Heredia, Bernhard Gehr, Sylvia Franc, Guillaume Charpentier
Publikováno v:
Diabetes, Obesity and Metabolism. 25:1607-1613
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b79cdddd7756a1e77e5aef42f2388ab
https://doi.org/10.1111/dom.15008
https://doi.org/10.1111/dom.15008
Autor:
Akram Imam, Eva C. Winnebeck, Nina Buchholz, Philippe Froguel, Amélie Bonnefond, Michele Solimena, Anna Ivanova, Michel Bouvier, Bianca Plouffe, Guillaume Charpentier, Angeliki Karamitri, Ralf Jockers, Till Roenneberg, Céline Vetter
Publikováno v:
Frontiers in Physiology, Vol 11 (2020)
BackgroundMelatonin modulates circadian rhythms in physiology and sleep initiation. Genetic variants of the MTNR1B locus, encoding the melatonin MT2 receptor, have been associated with increased type 2 diabetes (T2D) risk. Carriers of the common intr
Externí odkaz:
https://doaj.org/article/65a546bac6724efbbbee68d4f015b530
Autor:
Pierre-Yves Benhamou, ProfMD, Sylvia Franc, MD, Yves Reznik, ProfMD, Charles Thivolet, ProfMD, Pauline Schaepelynck, MD, Eric Renard, ProfMD, Bruno Guerci, ProfMD, Lucy Chaillous, MD, Celine Lukas-Croisier, MD, Nathalie Jeandidier, ProfMD, Helene Hanaire, ProfMD, Sophie Borot, MD, Maeva Doron, Pierre Jallon, Ilham Xhaard, PhD, Vincent Melki, MD, Laurent Meyer, MD, Brigitte Delemer, ProfMD, Marie Guillouche, MD, Laurene Schoumacker-Ley, MD, Anne Farret, MD, Denis Raccah, ProfMD, Sandrine Lablanche, MD, Michael Joubert, ProfMD, Alfred Penfornis, ProfMD, Guillaume Charpentier, MD
Publikováno v:
The Lancet: Digital Health, Vol 1, Iss 1, Pp e17-e25 (2019)
Summary: Background: Closed-loop insulin delivery systems are expected to become a standard treatment for patients with type 1 diabetes. We aimed to assess whether the Diabeloop Generation 1 (DBLG1) hybrid closed-loop artificial pancreas system impro
Externí odkaz:
https://doaj.org/article/bf42d9c4d29145c98bb3dcf6ec9f667f
Autor:
Anne Vambergue, Madleen Lemaitre, Chesner Desir, Thibault Le Roux Mallouf, Yoursa Tourki, Sylvia Franc, Sandrine Lablanche, Damien Subtil, Guillaume Charpentier, Pierre Yves Benhamou
Publikováno v:
Diabetes Technology & Therapeutics. 24:672-674
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::920752c92093874f5ed1e0c2a97bd071
https://doi.org/10.1089/dia.2022.0043
https://doi.org/10.1089/dia.2022.0043